Clinical Trial Detail

NCT ID NCT02971748
Title Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

inflammatory breast carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST